Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewNovel, potent, non-competitive AMPA receptor antagonist (IC50 = 2.8 μM ). Acts allosterically at the same regulatory site as GYKI 52466 (Cat. No. 1454) and GYKI 53655 (Cat. No. 2555) and other benzodiazepines but does not bind to the central diazepine binding site. Selective for AMPA relative to kainate receptor sub-types. Similar potency to GYKI 53655. Anticonvulsant in vivo.
Sold with the permission of Annovis Inc.
M. Wt | 366.42 |
Formula | C20H22N4O3 |
Storage | Store at RT |
Purity | ≥99% (HPLC) |
CAS Number | 173952-44-8 |
PubChem ID | 5039877 |
InChI Key | OFUDZKKOKPGXOH-UHFFFAOYSA-N |
Smiles | CCCNC(=O)N1N=C(C2=CC=C(N)C=C2)C2=C(C=C3OCOC3=C2)C1C |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Bleakman et al (2002) Kainate receptor agonists, antagonists and allosteric modulators. Curr.Pharm.Des. 8 873 PMID: 11945137
Pelletier et al (1996) Substituted 1,2-dihydrophthalazines: potent, selective and non-competitive inhibitors of the AMPA receptor. J.Med.Chem. 39 343 PMID: 8558499
Li et al (1999) Kainate-receptor-mediated sensory synaptic transmission in mammalian spinal cord. Nature 397 161 PMID: 9923678
Keywords: SYM 2206, SYM 2206 supplier, Non-competitive, AMPA, antagonist, Glutamate, Receptors, iGlur, Ionotropic, SYM2206, 0961, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for SYM 2206 include:
Nygaard et al (2015) Melanoma brain colonization involves the emergence of a brain-adaptive phenotype. J Neurophysiol 1 82 PMID: 25593989
Roopun et al (2010) Cholinergic neuromodulation controls directed temporal communication in neocortex in vitro. Front Neural Circuits 4 8 PMID: 20407636
Steullet et al (2014) Fast oscillatory activity in the anterior cingulate cortex: DArgic modulation and effect of perineuronal net loss. Front Cell Neurosci 8 244 PMID: 25191228
Randall et al (2011) Fast oscillatory activity induced by kainate receptor activation in the rat basolateral amygdala in vitro. Eur J Neurosci 33 914 PMID: 21255131
Kopach et al (2011) Inflammation alters trafficking of extrasynaptic AMPA receptors in tonically firing lamina II neurons of the rat spinal dorsal horn. Pain 152 912 PMID: 21282008
Liu et al (2004) Astrocyte-mediated activation of neuronal kainate receptors. Oncoscience 101 3172 PMID: 14766987
Satake et al (2006) Characterization of AMPA receptors targeted by the climbing fiber transmitter mediating presynaptic inhibition of GABAergic transmission at cerebellar interneuron-Purkinje cell synapses. J Neurosci 26 2278 PMID: 16495455
There are currently no reviews for this product. Be the first to review SYM 2206 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.